Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
Provided By GlobeNewswire
Last update: Aug 11, 2025
Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b program for NXP900.
Read more at globenewswire.com
